These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8906287)

  • 1. Effects of tryptophan related compounds on nuclear regulatory control. Possible role in the eosinophilia-myalgia syndrome.
    Sidransky H; Verney E; Latham P; Schwartz A
    Adv Exp Med Biol; 1996; 398():343-50. PubMed ID: 8906287
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthesis and analysis of contaminants in ems-related tryptophan.
    Steinhart H; van Wickern B; Meyer K; Simat T
    Adv Exp Med Biol; 1996; 398():667-75. PubMed ID: 8906342
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative studies on tryptophan binding to hepatic nuclear envelopes in Sprague-Dawley and Lewis rats.
    Sidransky H; Verney E
    Am J Physiol; 1994 Aug; 267(2 Pt 2):R502-7. PubMed ID: 8067461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of tissue distribution and excretion among three substances implicated in eosinophilia-myalgia syndrome.
    Adachi J; Ueno Y; Tatsuno Y; Gomez M; Smith CC; Sternberg EM
    Adv Exp Med Biol; 1996; 398():365-70. PubMed ID: 8906290
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of 3-phenylamino-L-alanine on tryptophan binding to rat hepatic nuclear envelopes.
    Sidransky H; Verney E; Cosgrove JW; Latham PS
    Toxicology; 1994 Jan; 86(1-2):135-45. PubMed ID: 8134920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies with 1,1'-ethylidenebis(tryptophan), a contaminant associated with L-tryptophan implicated in the eosinophilia-myalgia syndrome.
    Sidransky H; Verney E; Cosgrove JW; Latham PS; Mayeno AN
    Toxicol Appl Pharmacol; 1994 May; 126(1):108-13. PubMed ID: 8184420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eosinophilia myalgia syndrome. The role of contaminants, the role of serotonergic metabolism set up.
    Nicolodi M; Sicuteri F
    Adv Exp Med Biol; 1996; 398():351-7. PubMed ID: 8906288
    [No Abstract]   [Full Text] [Related]  

  • 8. The eosinophilia-myalgia syndrome and tryptophan.
    Belongia EA; Mayeno AN; Osterholm MT
    Annu Rev Nutr; 1992; 12():235-56. PubMed ID: 1503805
    [No Abstract]   [Full Text] [Related]  

  • 9. 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome?
    Mayeno AN; Belongia EA; Lin F; Lundy SK; Gleich GJ
    Mayo Clin Proc; 1992 Dec; 67(12):1134-9. PubMed ID: 1469924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.
    Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM
    Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome.
    Johnson KL; Klarskov K; Benson LM; Williamson BL; Gleich GJ; Naylor S
    J Rheumatol; 1999 Dec; 26(12):2714-7. PubMed ID: 10606395
    [No Abstract]   [Full Text] [Related]  

  • 12. The eosinophilia-myalgia syndrome and the toxic oil syndrome. Pursuing parallels.
    Hertzman PA
    Adv Exp Med Biol; 1996; 398():339-42. PubMed ID: 8906286
    [No Abstract]   [Full Text] [Related]  

  • 13. [Topics on eosinophilia-myalgia syndrome].
    Kamatani N
    Nihon Naika Gakkai Zasshi; 1991 Nov; 80(11):1782-7. PubMed ID: 1783846
    [No Abstract]   [Full Text] [Related]  

  • 14. Is there any relationship between eosinophilia myalgia syndrome (EMS) and fibromyalgia syndrome (FMS)? An analysis of clinical and immunological data.
    Barth H; Berg PA; Klein R
    Adv Exp Med Biol; 1999; 467():487-96. PubMed ID: 10721092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accumulation of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in blood and organs of the Lewis rats.
    Adachi J; Gomez M; Smith CC; Sternberg EM
    Arch Toxicol; 1995; 69(4):266-70. PubMed ID: 7755488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of four metabolites of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in rats.
    Adachi J; Mio T; Ueno Y; Naito T; Nishimura A; Fujiwara S; Sumino K; Tatsuno Y
    Arch Toxicol; 1994; 68(8):500-5. PubMed ID: 7802590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of decomposition products of 1,1'-ethylidenebis [L-tryptophan], a compound associated with eosinophilia-myalgia syndrome.
    Driskell WJ; Ashley DL; Grainger J; Sirimanne SR; Mazzola EP; Page SW; Needham LL; Hill RH
    Bull Environ Contam Toxicol; 1992 May; 48(5):679-87. PubMed ID: 1504513
    [No Abstract]   [Full Text] [Related]  

  • 18. Pathogenesis of L-tryptophan eosinophilia myalgia syndrome.
    Sternberg EM
    Adv Exp Med Biol; 1996; 398():325-30. PubMed ID: 8906284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eosinophilia-myalgia syndrome or fibromyalgia with eosinophilia?
    Hudson JI; Pope HG; Daniels SR; Horwitz RI
    JAMA; 1993 Jun 23-30; 269(24):3108-9. PubMed ID: 8505810
    [No Abstract]   [Full Text] [Related]  

  • 20. Subchronic toxicity of 3-phenylamino alanine, an impurity in L-tryptophan reported to be associated with eosinophilia-myalgia syndrome.
    Sato F; Hagiwara Y; Kawase Y
    Arch Toxicol; 1995; 69(7):444-9. PubMed ID: 8526739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.